Tonawanda, NY – March 7, 2024 – Pine Pharmaceuticals, one of the nation’s largest and most trusted FDA-registered 503B outsourcing facilities, has announced the launch of moxifloxacin 0.5 mg and 0.75 mg, now available in ready-to-use vials. These latest additions reinforce Pine Pharmaceuticals’ commitment to providing high-quality compounded and repackaged preparations that meet the evolving needs of health systems nationwide.
“With a decade of experience in the industry, we understand how critical it is for healthcare providers to have reliable access to the drug products they need to care for their patients,” said Alfonse J. Muto, Pharm.D. “That’s why we’re excited to introduce moxifloxacin in new containers that are convenient and affordable.”
Last year, Pine Pharmaceuticals also introduced norepinephrine 32 mg—the latest addition to its expanding line of ready-to-administer premix IV bags. Looking ahead, the company remains dedicated to launching new products that support healthcare providers, improve patient care, and address ongoing drug shortages.
“We are always exploring ways to provide cost-effective solutions for healthcare professionals,” Muto added. “Whether it is expanding our product catalog or refining existing offerings, our goal is to deliver reliable, high-quality drug products that improve patient outcomes.”
About Pine Pharmaceuticals LLC
Pine Pharmaceuticals is an FDA-registered 503B outsourcing facility that specializes in the preparation of high-quality, ready-to-administer compounds and repackaged products. As a best-in-class partner, Pine Pharmaceuticals is committed to meeting the FDA’s stringent cGMP requirements while supporting hospitals, surgery centers, and practices nationwide. For more information, please visit www.pinepharmaceuticals.com or call 844-218-4138 to learn more about our products and services.
©2025 Pine Pharmaceuticals. All rights reserved.